Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer

This trial is studying chemotherapy combined with two additional drugs — adebrelimab (an immunotherapy) and apatinib (a targeted therapy) — as a treatment given before and after surgery for patients with intrahepatic cholangiocarcinoma, which is a type of bile duct cancer found inside the liver. **You may be eligible if...** - You have been diagnosed with intrahepatic cholangiocarcinoma (bile duct cancer inside the liver) - Your tumor is considered removable with surgery - You are at high risk of the cancer coming back after surgery - You have not yet had systemic (whole-body) treatment for this cancer - You are in good physical condition (ECOG 0-1) and your liver function is good (Child-Pugh A) **You may NOT be eligible if...** - You have had recent gastrointestinal bleeding (within 6 months) - You have had abdominal fistulas, perforation, or abscesses recently - You have bleeding or blood clotting disorders - You have had a blood clot event within the last 6 months - You have uncontrolled heart disease or high blood pressure Talk to your doctor to see if this trial is right for you.